Let's translate scientific complexity into real-world application to show how our drug can and will help millions.
Hypoestoxide inhibits tumor growth by 60-70% in mice. It works by shutting off blood supply to the tumor, essentially starving the tumor to death. This makes it an effective chemotherapeutic agent against malignant tumors.
It combines well with 5-Fluorouracil (5-FU)—the standard anti-colon cancer drug—and reduces the toxic dose of 5-FU by 4-fold, without compromising efficacy. Whereas most anti-cancer drugs are administer by intravenous infusions and are toxic (resulting in weight-loss, hair-loss and appetite-loss), Hypoestoxide is orally bio-available and non-toxic.
Hypoestoxide is a Non-steroidal-anti-inflammatory-drug (NSAID). It surpasses the standard NSAIDs such as Celebrex, Vioxx, Bextra and Aspirin because unlike them, it does not lead to gastric bleeding, heart dysfunction or platelet damage. Hypoestoxide is comparable to Dexamethasone in reducing inflammatory effects of collagen-induced arthritis (CIA) in rats (57% versus 63%). Yet Dexamethasone is a steroid and Hypoestoxide is not. Which one of these two drugs would you rather have in your body?
Extremely low doses of Hypoestoxide (0.25mg/kg) significantly reduces blood malaria parasitemia levels by 90% in mice. In a preliminary proof of concept, Hypostoxide totally cleared blood parasitemia in 5 out of 6 patients and fully resolved malaria-induced fever in all patients. Hypoestoxide is 20 times more effective than Chloroquine in reducing malaria-induced infection in mice and rats (0.25mg/kg versus 5 mg/kg).
Hypoestoxide is effective in inhibiting the intracellular development of HIV, Herpex simplex-1 (HSV-1), and Herpes simplex-2 (HSV-2) viruses in vitro. Certain strains of HIV are particularly susceptible to the cytopathic effects (damage to host cells during virus invation) of Hypoestoxide. In laboratory mice, when HSV-2 is administered intraperitoneally, the virus migrates to the brain to cause encephalitis (inflammation of the brain). Hypoestoxide totally inhibits encephalitis in HSV-2 infected mice treated with the drug.
Hypoestoxide is effective in reducing the accumulation of specific proteins (alpha-synuclein) responsible for the pathology of Parkinson's disease (PD) in a transgenic mouse model of the disease. Hypoestoxide actually alters the course of PD progression, preventing the loss of dopaminergic neurons and ameliorating motor behavioral deficits in the transgenic mouse model of PD.
Kala-Azar is a disease caused by infection with leishmania parasites, transmitted through the bites of sandflies. The disease is also known as Visceral Leishmaniasis. It is the second largest parasitic killer in the world—only Malaria is more deadly. Hypoestoxide has been shown to be selectively effective against Leishmania amastigotes residing inside of macrophages. Hypoestoxide-treated infected macrophages were vacuolated, demonstrating the elimination of intracellular amastigotes. Our drug is more active in vitro against Leishmania than the standard drug Miltefosine, by 20-fold.